What You Should Know: Quest Diagnostics announced that it has completed its $450M acquisition of Haystack Oncology.Haystack Oncology has developed a highly sensitive minimal-residual disease (MRD) testing technology, based on circulating tumor DNA (ctDNA), to aid in the early detection of residual or recurring cancer and better inform therapy decisions.Acquired back in April, the acquisition […]
